oxurion
nv
appoints
tom
graney
cfa
chief
financial
officer
oxurion
nv
appoints
tom
graney
cfa
chief
financial
officer
former
vertex
generation
bio
cfo
brings
significant
operational
us
capital
markets
investor
relations
expertise
leuven
belgium
boston
usa
october
cet
oxurion
nv
euronext
brussels
oxur
biopharmaceutical
company
developing
next
generation
therapies
diabetic
macular
edema
dme
pleased
announce
appointment
tom
graney
chief
financial
officer
cfo
graney
begin
role
october
based
boston
us
succeed
dominique
vanfleteren
according
plan
leaving
oxurion
pursue
interests
graney
responsible
extension
execution
financial
strategy
support
oxurion
ambitious
global
growth
plans
including
important
us
market
tom
years
experience
senior
finance
strategy
operational
roles
including
capital
raising
accounting
audit
recently
served
cfo
generation
bio
nasdaq
gbio
gene
therapy
company
based
cambridge
led
company
financial
operations
prior
joining
generation
bio
tom
senior
vice
president
svp
cfo
vertex
pharmaceuticals
nasdaq
vrtx
one
world
highly
valued
biotech
companies
turnover
vertex
tom
responsible
financial
strategy
operations
including
finance
accounting
internal
audit
functions
prior
vertex
cfo
svp
finance
corporate
strategy
ironwood
pharmaceuticals
nasdaq
irwd
healthcare
company
joining
ironwood
tom
spent
years
johnson
johnson
serving
various
roles
us
abroad
including
worldwide
vp
finance
cfo
ethicon
major
medical
device
company
vp
cfo
janssen
pharmaceuticals
na
major
pharmaceutical
company
north
america
tom
currently
board
ac
immune
sa
nasdaq
aciu
clinical
stage
swiss
biopharmaceutical
company
focused
neurodegenerative
diseases
tom
holds
bachelor
science
degree
accounting
university
delaware
master
business
administration
marketing
finance
international
business
leonard
stern
school
business
new
york
university
tom
also
cfa
charterholder
delighted
welcome
tom
oxurion
convinced
tom
significant
financial
management
us
capital
markets
experience
enable
play
crucial
role
successful
execution
plans
develop
industry
leading
franchise
treatment
dme
currently
billion
annual
market
opportunity
tom
grace
recently
appointed
cmo
based
us
starting
build
transatlantic
organization
need
deliver
global
ambition
behalf
board
would
like
take
opportunity
thank
dominique
contribution
oxurion
last
years
agreeing
support
us
ensure
smooth
transition
would
like
wish
every
success
future
said
dr
patrik
de
haes
ceo
oxurion
tom
graney
newly
appointed
cfo
oxurion
added
excited
opportunity
work
patrik
team
oxurion
believe
oxurion
two
highly
differentiated
new
drug
candidates
potential
address
needs
nearly
patients
dme
serious
sight
threatening
condition
looking
forward
using
experience
ensure
oxurion
continued
access
financial
resources
needed
achieve
ambitious
corporate
oxurion
virtual
r
investor
day
take
place
thursday
october
cet
et
please
consult
oxurion
website
registration
call
details
follow
link
https
oxurion
ffdl
end
information
please
contact
oxurion
nv
dr
patrik
de
haes
ceo
tel
citigate
dewe
rogerson
david
dible
sylvie
berrebi
frazer
hall
tel
oxurion
oxurion
oxurion
euronext
brussels
oxur
biopharmaceutical
company
developing
next
generation
standard
care
ophthalmic
therapies
designed
better
preserve
vision
patients
diabetic
macular
edema
dme
leading
cause
vision
loss
diabetic
patients
worldwide
oxurion
building
leading
global
franchise
treatment
dme
based
successful
development
two
novel
therapeutics
plasma
kallikrein
inhibitor
developed
potential
new
standard
care
dme
patients
respond
therapy
shown
positive
topline
phase
results
treatment
dme
company
currently
conducting
phase
clinical
trial
evaluating
previously
responded
therapy
developed
conjunction
bicycle
therapeutics
plc
nasdaq
bcyc
integrin
inhibitor
initially
developed
potential
new
standard
care
dme
patients
positive
topline
results
phase
clinical
study
assessing
treatment
dme
announced
january
expected
enter
phase
clinical
trial
optimized
compound
derived
broader
library
integrin
inhibitors
galapagos
nv
euronext
nasdaq
glpg
oxurion
headquartered
leuven
belgium
listed
euronext
brussels
exchange
symbol
oxur
information
available
important
information
statements
certain
statements
press
release
may
considered
statements
based
current
expectations
accordingly
entail
influenced
various
risks
uncertainties
company
therefore
provide
assurance
statements
materialize
assume
obligation
update
revise
statement
whether
result
new
information
future
events
reason
additional
information
concerning
risks
uncertainties
affecting
business
factors
could
cause
actual
results
differ
materially
statement
contained
company
annual
report
press
release
constitute
offer
invitation
sale
purchase
securities
assets
oxurion
jurisdiction
securities
oxurion
may
offered
sold
within
united
states
without
registration
securities
act
amended
compliance
exemption
therefrom
accordance
applicable
state
securities
laws
